These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7875519)

  • 21. Comparison of an EBV transformed cell line and an EBV hybridoma cell line producing the same human anti-HBs monoclonal antibody.
    Sa'adu A; Walker H; Locniskar M; Bidwell D; Howard C; McAdam KP; Voller A
    J Virol Methods; 1992 Apr; 37(1):1-11. PubMed ID: 1315325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Curr Opin Mol Ther; 2010 Dec; 12(6):734-40. PubMed ID: 21154165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The expediency of producing antirhesus-Rh0(D) immunoglobulin and its use for preventing hemolytic disease of the newborn (for discussion)].
    Mikhaĭlova AA; Klimova NIa
    Gematol Transfuziol; 1992; 37(7-8):39-40. PubMed ID: 1342987
    [No Abstract]   [Full Text] [Related]  

  • 25. Monoclonal anti-D for immunoprophylaxis.
    Scott ML
    Vox Sang; 2001 Nov; 81(4):213-8. PubMed ID: 11903995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Obtention of a heterohybridoma for production of type IgM monoclonal antibodies against the D antigen of the Rh system].
    León-González G; Cruz C
    Invest Clin; 2007 Mar; 48(1):57-67. PubMed ID: 17432544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn.
    Nielsen LK; Green TH; Sandlie I; Michaelsen TE; Dziegiel MH
    Transfusion; 2008 Jan; 48(1):12-9. PubMed ID: 17764508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-D (again!)--tell me the old, old story..
    Mitchell R
    Scott Med J; 1994 Oct; 39(5):138. PubMed ID: 8778967
    [No Abstract]   [Full Text] [Related]  

  • 30. [Perinatal hemolytic disease. Part 2: Prevention and management].
    Hohlfeld P; Wirthner D; Tissot JD
    J Gynecol Obstet Biol Reprod (Paris); 1998 Apr; 27(3):265-76. PubMed ID: 9648004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas.
    Thompson KM; Melamed MD; Eagle K; Gorick BD; Gibson T; Holburn AM; Hughes-Jones NC
    Immunology; 1986 May; 58(1):157-60. PubMed ID: 3011653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
    Brinc D; Lazarus AH
    Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists.
    Urbaniak SJ
    Transfusion; 1998 Jan; 38(1):97-9. PubMed ID: 9482402
    [No Abstract]   [Full Text] [Related]  

  • 34. Diagnosis and treatment of severe alloimmunization.
    Bennebroek Gravenhorst J
    Vox Sang; 1994; 67 Suppl 3():235-8. PubMed ID: 7975499
    [No Abstract]   [Full Text] [Related]  

  • 35. The continuing struggle to eliminate hemolytic disease of the newborn from RH (D).
    Barlow JF
    S D J Med; 1999 Jan; 52(1):7-8. PubMed ID: 9926725
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?
    Brinc D; Denomme GA; Lazarus AH
    Curr Opin Hematol; 2009 Nov; 16(6):488-96. PubMed ID: 19730101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed?
    Harding K
    Br J Obstet Gynaecol; 1997 Jul; 104(7):869-70. PubMed ID: 9236664
    [No Abstract]   [Full Text] [Related]  

  • 38. Preventing RhD haemolytic disease of the newborn.
    van Dijk B
    BMJ; 1997 Dec; 315(7121):1480-1. PubMed ID: 9420481
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-D in a mother, hemizygous for the variant RHD*DNB gene, associated with hemolytic disease of the fetus and newborn.
    Quantock KM; Lopez GH; Hyland CA; Liew YW; Flower RL; Niemann FJ; Joyce A
    Transfusion; 2017 Aug; 57(8):1938-1943. PubMed ID: 28639307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected suppression of anti-Fya and prevention of hemolytic disease of the fetus and newborn after administration of Rh immune globulin.
    Branch DR; Scofield TL; Moulds JJ; Swanson JL
    Transfusion; 2011 Apr; 51(4):816-9. PubMed ID: 20946183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.